Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171777 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
- 20
- Study locations
NCT05171777 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 179 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05171777, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).
Conditions Studied
Interventions
- DRUG Atezolizumab
Study Locations (20)
Other
- Fundación CENIT para la Investigación en Neurociencias - Buenos Aires
- CEMIC - Buenos Aires
- Centro Oncologico Korben - Ciudad Autonoma Buenos Aires
- OrlandiOncología - Santiago
- Clinica CIMCA - San José
- ICIMED Instituto de Investigación en Ciencias Médicas - San José
- Oulun yliopistollinen sairaala (OYS) - Oulu
- Tampereen yliopistollinen sairaala (TAYS) - Tampere
- Turun yliopistollinen keskussairaala (TYKS) - Turku
- Vaasan Keskussairaala - Vaasa
Rio Grande do Sul
- Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda - Ijuí
- Hospital das Clinicas - UFRGS - Porto Alegre
- Hospital Nossa Senhora da Conceicao - Porto Alegre
Ontario
- Royal Victoria Regional Health Centre - Barrie
- Sault Area Hospital - Sault Ste. Marie
New Jersey
- New Jersey Hematology Oncology Associates LLC - Brick
Ohio
- Tri County Hematologyoncology - Massillon
Oregon
- Asante Rogue Regional Medical Center - Medford
Pennsylvania
- UPMC - Hillman Cancer Center - Pittsburgh
São Paulo
- Instituto do Cancer do Estado de Sao Paulo - ICESP - São Paulo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05171777
The ClinicalTrials.gov registry entry for NCT05171777 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Atezolizumab is the first listed.
NCT05171777 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Rio Grande do Sul, Ontario.
Frequently Asked Questions
What is clinical trial NCT05171777 about?
NCT05171777 is a clinical study titled "A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer". This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemother...
What is the current status of trial NCT05171777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2022-04-04. Estimated completion is 2024-10-25.
What conditions does trial NCT05171777 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05171777?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT05171777?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05171777 being conducted?
This trial has 20 study locations across New Jersey, Ohio, Oregon, Pennsylvania, Rio Grande do Sul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.